Podcasts about ADT

Jessica Zwaan joined us on The Modern People Leader for MPL Build's first-ever AMA, alongside Jalene Vandermey-Jackson from Workleap. We talked about what traditional HR mindsets must be let go to become builders, how to collect lightweight employee feedback to help build the right products, and more.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode284Sponsor Links:

Diane Sadowski-Joseph, Co-Founder of Clarinet, joined us on The Modern People Leader. We talked about why most AI adoption stalls at “talking the talk,” how to choose the right AI use cases using the “trifecta” and the Five Frictions framework, and how “click cutters” can unlock compounding gains by removing cognitive and workflow friction.----  Here's everything Diane referenced: https://modernpeopleleader.kit.com/fivefrictionsSponsor Links:

Send a textWhat does it take for a hard-headed MIT engineer to become a full-time healer? For Brent Michael Phillips, it started with a brutal collapse: hundred-hour weeks, chronic pain that medicine couldn't solve, and a surgery that left his right arm paralysed. Then came a single session with a healer named Terry, a loud pop at the elbow, and immediate movement. The miracle sparked a bigger mission—could this be reverse engineered into a clear, teachable method?We dive into Brent's decade-long quest to decode what gifted practitioners do, translating intuition, energy work, and meditative states into “consciousness technology” anyone can learn. Brent explains why the subconscious runs the show, how to test and rewrite deep code, and why many classic manifesting tools feel like riding a horse on a motorway: nostalgic, not efficient. He shares how ADT brings precision to healing and results, and how health outcomes shift when we add mind-level interventions alongside conventional care for chronic issues.We also press into the data behind past-life memories, genetics as baseline software, and why you rarely need to chase metaphysical archives to change your life. The practical gold lands in micro-habits: send unconditional love for 30 seconds a day and clear your space at home, work, and in the car. Anchor them to your morning routine and let small, consistent moves compound into calmer rooms, clearer sessions, and better outcomes.If you've craved a grounded bridge between science and spirit, this conversation brings a blueprint: testable tools, everyday practices, and a way to treat consciousness with the same respect we give electricity—useful, scalable, and ready to power real change. Subscribe, share with a friend who's curious, and leave a review with the one habit you'll try this week.Music from #Uppbeat (free for Creators!):https://uppbeat.io/t/sky-toes/featherlightLicense code: ZTXJPK8BA5WMLKSF My new novel The Red Magus has recently been published in conjunction with the Unbound Press. An entralling mystical adventure set across time and space, where past and current lives converge. Find it on Amazon and Barnes & Noble. A call to action to help us keep spreading the spiritual ripple xxSupport the showBe a Compassion Crusader!Please like, share and subscribe!https://www.buzzsprout.com/1827829/supporters/newNatasha Joy Pricewww.dandeliontherapies.co.ukFacebook - Dandelion TherapiesInstagram - natashapriceauthor Books:- Freedom of the Soul - available on Amazon UK The Red Magus - available on Amazon and Barnes & Noble.

Liz Bronson, VP of People at Skimmer, joined us on The Modern People Leader to talk about intentionally “flatlining” her career for a period of time to prioritize parenting. ----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode282Sponsor Links:

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next-generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC). Bokhari told Proactive that the Teverelix trial will be conducted as a Phase 2b open-label study enrolling approximately 40 men with advanced prostate cancer who are appropriate candidates for androgen deprivation therapy (ADT). Patients will undergo treatment for approximately 22 weeks. The study's primary endpoint is confirmation of medical castration by Day 29, with sustained testosterone suppression maintained through Day 155. The company is targeting a probability of success exceeding 90% for achieving this endpoint. Teverelix trifluoroacetate is formulated as a long-acting injectable GnRH antagonist delivered as a microcrystalline suspension. Unlike GnRH agonists—which typically cause an initial surge in testosterone levels before suppression—Teverelix works through immediate receptor antagonism. This mechanism enables rapid suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and downstream sex hormones without the testosterone “flare” associated with agonist therapies. This rapid suppression profile may hold particular clinical relevance for patients with advanced prostate cancer who are at elevated cardiovascular risk. Emerging evidence suggests that persistent FSH exposure in patients treated with GnRH agonists may contribute to adverse cardiovascular outcomes. While further clinical validation is required, prior Teverelix studies have not demonstrated significant cardiovascular safety signals to date. Cardiovascular disease remains one of the leading causes of non-cancer mortality in men with prostate cancer, accounting for approximately 30% of deaths. The risk can be further amplified during androgen deprivation therapy, particularly among patients with pre-existing cardiovascular disease. Clinical and observational data indicate that such patients may face a five- to six-fold higher incidence of major adverse cardiovascular events (MACE) when treated with GnRH agonists compared to GnRH antagonists. With FDA clearance now secured, Medicus Pharma is preparing to advance the Phase 2b study as it continues to evaluate Teverelix's potential as a differentiated therapeutic option in the treatment of advanced prostate cancer. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #Teverelix #ProstateCancer #AdvancedProstateCancer #Oncology #ClinicalTrials #Phase2b #FDA #AndrogenDeprivationTherapy #GnRH #BiotechInnovation #CardiovascularRisk #CancerResearch #DrugDevelopment #HealthcareInnovation

Isabel Naidoo, Chief People Officer at Wise, joined us on The Modern People Leader to share how Wise builds a cohesive employee experience across global offices while still honoring local identity. ----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode281Sponsor Links:

Chase Warrington, Head of Operations at Doist, joined us on The Modern People Leader to break down how async-first work enables faster decision-making, stronger culture, and scalable operations. We talked about building trust without offices, the systems and rituals behind Doist's execution velocity, and why async workflows are foundational to effective AI adoption.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode280Sponsor Links:

In this episode of the ACRO Podcast, ACRO Committee Member Dr. Nevine Hanna is joined by radiation oncologist Dr. Christopher Lee to discuss how genomic testing is refining risk stratification for patients with intermediate risk prostate cancer. He shares insights on integrating genomic data with clinical factors to guide decisions around active surveillance, radiation therapy, and determining which patients may benefit from androgen deprivation therapy (ADT) post-radiation. The conversation highlights practical takeaways for clinicians focused on more personalized, evidence based prostate cancer care.This episode of the ACRO Podcast is sponsored by Myriad Oncology.

Jani Sanguino joined us on The Modern People Leader to share how Viva built an award-winning, manager-led AI transformation. We talked about the three AI competencies they prioritized, their 13-week manager-led learning path, and the most impactful use cases for their business.----  Go deeper on Viva's AI Journey in Roundtable with Jani (only 10 seats)Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode279----Sponsor Links:

We recapped MPL Live Austin with attendees Cindy Lopez (Senior Director, People & Culture, Pattern Bioscience) and Marlene Arroyo (Founder, Peoplecraft).----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode278Sponsor Links:

Jon Couture, CHRO at Vanguard, joined The Modern People Leader to share how Vanguard is balancing 50 years of legacy with the next 50 years of change. ----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode277Sponsor Links:

Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients treated with ADT alone, ADT and an ARPI, ADT and docetaxel, and ADT, an ARPI, and docetaxel whose disease has progressed to mCRPC and the evidence that underpins these changes. Dr. Taplin highlights the updated algorithms within the guideline and the living format which will provide rapid, up-to-date, evidence-based information for clinicians and patients. Read the full living guideline update, "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." at www.asco.org/genitourinary-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02693 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Mary-Ellen Taplin from Dana-Farber Cancer Institute, lead author on "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." Thank you for being here today, Dr. Taplin. Dr. Mary-Ellen Taplin: Thank you, Brittany. It is a pleasure. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Taplin who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To dive into the content here and what we are here today to talk about, this living clinical practice guideline for systemic therapy for patients with metastatic castration-resistant prostate cancer is updated on an ongoing basis. Dr. Taplin, what prompted this latest update to the recommendations? Dr. Mary-Ellen Taplin: Thank you, Brittany. Several things prompted the latest update. There have been several phase III trials that have been practice-changing that have resulted in the last several years that needed to be added to the guidelines to inform clinicians of comprehensive treatment options. Brittany Harvey: Great, and it is great to have this updated guideline for readers. I would like to review the changes to the recommendations in this latest iteration across the patient populations that are outlined in the guideline. So, starting with: What are the updated recommendations for patients previously treated with androgen deprivation therapy alone whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: A nice feature of this guideline is that in addition to the tables, which provide detailed options, is at the end of the guidelines, our readers will find very clear algorithms that describe past treatment scenarios that patients could have had and then outline their treatment options. So it is very clear. Our clinicians will love these algorithms. And one of the changes for the disease state that you mentioned, which is the least treated castration-resistant state of prostate cancer which is previously treated with ADT alone, is that we recommend testing for mutations in the HRR, homologous recombination repair, genes. And the ones that are specifically known and applicable to prostate cancer are the BRCA genes. So there is clear recommendation of testing to remind us, as treating physicians, that now is the time, if it hasn't been done before, to institute both germline and somatic testing. And somatic testing, if it can be done on tissue, is preferable, but if not, the liquid biopsy approaches, the ctDNA approaches, have now advanced to the point that most patients with metastatic prostate cancer will be able to successfully have testing on the liquid biopsies. So that is number one, testing. And then the new treatment options include, if a patient does have an HRR gene alteration, and maybe about 20-25 percent of patients will be in that category, the combinations of an androgen pathway inhibitor and a PARP inhibitor are now treatment options. So for instance, talazoparib and enzalutamide; olaparib and abiraterone; or niraparib and abiraterone are some of the newer treatment options if the patient is HRR-positive. So, Brittany, in regard to patients treated with ADT alone, another new treatment option is the combination of radium-223 with enzalutamide. This is data based on the PEACE-3 trial which did show both an rPFS and OS benefit. For the patient who is HRR-negative and has previously not had an ARPI, just ADT alone, the combination of radium and enzalutamide is a new recommendation added to the algorithm. Brittany Harvey: Great. Thank you for reviewing those options for that patient population. And as you mentioned, I think those algorithms are very helpful as figures in the document. They are clear and can be used as at-a-glance tools for clinicians in their busy clinics. So then the next patient population that the guideline addresses: What is new for patients previously treated with androgen deprivation therapy and an androgen receptor pathway inhibitor whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Right, so there are several new treatment options. So one is lutetium-PSMA-617, the trade name of which is Pluvicto. So that has now been FDA approved to use after progression on an AR pathway inhibitor and prior to the use of docetaxel chemotherapy. Brittany Harvey: Thank you for reviewing that new option for patients treated with androgen deprivation therapy and an ARPI whose disease has progressed. So then moving into the next set of recommendations, what does the panel now recommend for patients previously treated with androgen deprivation therapy and docetaxel whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: The next group of patients is those treated with ADT and docetaxel but haven't had an AR pathway inhibitor. Treatment options, again the HRR testing is important. So all patients with metastatic castration-resistant prostate cancer should be considered for both germline and somatic testing. I will repeat that. And if they are BRCA mutation positive, then the option of talazoparib and enzalutamide; olaparib and abiraterone; and niraparib and abiraterone.  So the AR pathway inhibitors plus the PARPs. There are three choices, so that can be somewhat complicated to think through, but most practitioners will get familiar with one of those combinations and be their go-to. So those are for BRCA-positive or HRR-positive. The talazoparib/enzalutamide trial also included non-BRCA HRR-positive gene mutations. And if they are HRR-negative, the option that we discussed above of radium and enzalutamide is new to the guideline. Brittany Harvey: Great. And then the last category of patients that is addressed in this update: What has changed for patients previously treated with androgen deprivation therapy, an androgen receptor pathway inhibitor, and docetaxel whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Well, in this space, patients who are heavily pretreated with ADT and ARPI, one or even two, and chemotherapy, generally with docetaxel, the recommendations are not new within the last year or two. And they include Pluvicto; a PARP inhibitor if HRR-positive and they have not had one; second-line chemotherapy such as cabazitaxel. And if they are a very rare group and they have been sequenced and they are MSI-high, then considering a PD-1 inhibitor such as pembrolizumab can be considered. I will note that this is a very small percentage of mCRPC patients, probably in the order of 5 percent or less. Brittany Harvey: Understood. And I appreciate you reviewing the recommendations across all of these patient populations. It sounds like some of the key points is that HRR testing is very important for this patient population, and that the algorithms and the tables in the manuscript provide the full list of options that clinicians and patients can refer to. Dr. Mary-Ellen Taplin: Those are the highlights. And I will note in the tables, all the sections have "Special Considerations" sections because patients never fall into the black and white of one category. And those practical information or special situations sections of each of the recommendations can also help clinicians think about the individual patient in front of them and how they might choose one therapy over another since there are generally choices in all of these treatment situations. Brittany Harvey: Absolutely. That information for the individualized patient-clinician decision-making is really key when, as you said, there is a list of options to choose from. So in your view, what should clinicians know as they implement this living guideline update, and how do these changes impact patients? Dr. Mary-Ellen Taplin: I am so excited about this living document. ASCO has invested to developing the software to, in real time and iteratively, assess the new data that is published in prostate cancer and other diseases. So now we don't have to wait many years for the next guideline to come out. The guidelines will be updated every six months in prostate cancer based on this automatic search of the literature and a standing panel of both academic and community experts in prostate cancer treatment. So we no longer have to wait. That is what makes this guideline stand out to other guidelines. And in the digestible format that we have made, a clinician can seek out the table and read some details, seek out practical information for the recommendations, or they can just go right to the clear figure algorithm and take a quick snapshot. "Yep, I need to do HR testing. Done. Oh, okay. HR-positive or negative, these are my options," and then think about the individual patient in front of them when there is more than one option. For instance, a patient with cardiovascular history, abiraterone might not be a good choice for them. Or a patient with neuropathy, docetaxel might not be a good choice for them. But, within this guideline, it really will be up to date and focused on the busy clinician and knowing what the options are for their patient. Brittany Harvey: Definitely. This new era of living guidelines is very exciting and can provide even more up-to-date, evidence-based recommendations to really support clinicians and patients with metastatic castration-resistant prostate cancer. So in that vein, finally, what is the panel examining, and what are you excited for for new data coming out for future updates to this living guideline? Dr. Mary-Ellen Taplin: The future updates will depend on the results of phase III clinical trials. You know, there are many phase III trials ongoing in advanced prostate cancer, some of which include targeted therapy, which has been long awaited in prostate cancer. So such compounds as antibody-drug conjugates that are targeting certain proteins in prostate cancer cells, such as STEAP1, KLK2, B7-H3. So I think we are entering a new era in prostate cancer where we will be targeting cells and delivering drugs and applying them to prostate cancer if the trials are positive. So I think with AI and a large investment in prostate cancer clinical drug development, I think the treatment options for our patients will be rapidly evolving in a manner not previously seen. So the guidelines need to follow along with these developments. Brittany Harvey: Definitely. It sounds like an exciting time for research in metastatic castration-resistant prostate cancer. And we will await the result of those phase III trials to inform this guideline and lead to future updates. So I want to thank you so much for your work to rapidly and continuously update these guidelines and for your time today, Dr. Taplin. Dr. Mary-Ellen Taplin: Oh, it was my pleasure. ASCO has been a leader in this area, and as a practicing clinician, we are thankful for the investment and guidance that ASCO gives us. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Mensagem do ADT.

In this episode of The Modern People Leader, Sarika Lamont, Chief People Officer at Vidyard, joins us to unpack her non-traditional journey into HR and how AI is reshaping the role of People teams. She shared practical AI use cases from onboarding automation to AI coaching, along with the mindset shifts HR leaders must make to lead change rather than fear it. ----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode276Sponsor Links:

We've moved past the "Geometry" of the beginner guide—it's time for the "Trigonometry". Kyle and Katie break down the advanced tactics that shift your mindset from "gambler" to "business partner".The Intel:The Dyno Tune: Why pros never change strategies on the felt.Doctor of Stackanomics: Mastering the 5-Stack system (Rapier Tiers & Side Bets).The Appearance Fee: Leveraging your ADT to negotiate hard comps.The Catalyst: The Kansas City trip that defined the 8th Core Koncept."The house owns the math; we own the transaction." +1

If you're 55, 60, 65+ and dealing with low energy, low libido, ED, or you've been told testosterone therapy (TRT) is dangerous for prostate cancer—this episode is for you. Dr. Geo sits down with Dr. Abraham Morgentaler (Harvard-trained), founder of the first comprehensive Men's Health Center in the U.S., co-founder of the Androgen Society, author of the bestseller Testosterone for Life, and winner of the 2024 Grandmaster in Testosterone Award.In this conversation, Dr. Morgentaler explains how the old “testosterone causes prostate cancer” dogma took hold, why it's being challenged, and what men should understand today about:✅ TRT and prostate cancer (past, present, and what's changing)✅ Why FREE testosterone matters more than total testosterone for symptoms✅ The importance of listening to patient symptoms, not just “a number”✅ Testosterone options: injections, gels/creams, pellets, oral testosterone✅ What men should ask their doctor if they have low testosterone, active surveillance, or history of prostate cancer treatmentThis episode is educational and designed to help you walk into your next doctor's visit with better questions and clearer understanding.⏱️ CHAPTERS00:00 — TRT + prostate cancer: the myth that won't die01:00 — Who is Dr. Abraham Morgentaler (why he matters) 04:00 — The Harvard lizard lab: how testosterone shaped his thinking10:00 — Pre-Viagra era + why he started testing testosterone in men18:00 — The turning point: finding prostate cancer in men with low T21:00 — Where the dogma came from (Huggins) + why it stuck 27:00 — Why younger men may be seeing lower testosterone (obesity, plastics, more)34:00 — Testosterone in advanced/metastatic prostate cancer: real cases + quality of life40:00 — BAT explained: bipolar androgen therapy (high/low testosterone cycling)45:00 — What patients should do today (TRT after treatment, ADT tradeoffs)51:00 — The “twin” story: why stopping TRT often makes no sense53:00 — Free testosterone vs total testosterone (what to focus on)01:02:00 — TRT options: injections vs gels vs pellets vs oral 01:08:00 — Where to find Dr. Morgentaler + final takeaways

Peter Fader and Jessica Zwaan joined The Modern People Leader to explore how customer-based audit principles can be applied to employees.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode275Sponsor Links:

Kirthi Mani, Chief People Officer at CLA, joins The Modern People Leader to explore why joy is a true competitive advantage and how people-first leadership drives sustainable performance. ----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode274Sponsor Links:

In this powerful episode of The Birth Lounge podcast, HeHe sits down with Rajia, the founder of InvisaWear, to talk about a reality far too many women know all too well: moving through the world while constantly calculating risk. Rajia shares the terrifying experience she had in college that sparked the creation of InvisaWear and why “just be more careful” is not, and has never been, an actual solution. Together, they unpack the deeply unsettling statistics around violence against women, where current safety systems fail us, and what real, practical protection can look like. You'll learn how InvisaWear discreetly weaves safety technology into everyday accessories like necklaces, bracelets, and even scrunchies, allowing you to alert trusted contacts or emergency services with the press of a button, without escalating a situation or drawing attention. The conversation also dives into self-defense strategies, rideshare safety, hiking alone, and the emotional toll of living on high alert. They also explore the bigger picture: why legislative change, community accountability, and shifting the responsibility off women's behavior and onto systems that actually protect us matters more than ever. This episode is equal parts validating, infuriating, and empowering. If you've ever gripped your keys a little tighter, shared your location “just in case,” or wished you had an extra layer of protection, this conversation is for you. Guest Bio: Rajia Abdelaziz started one of the fastest-growing companies in America when she was just 21 years old. Today, she is an award-winning entrepreneur revolutionizing the personal safety industry. Rajia is the Founder & CEO of invisaWear, a company that creates safety devices disguised as jewelry and accessories. With just two clicks, users can instantly alert friends, family, and-optionally-police. Her work has earned national acclaim. She's been featured on the cover of Forbes 30 Under 30 in the Social Impact category, named one of the most successful entrepreneurs in Massachusetts by the Boston Globe, and recognized on both the Inc. Female Founders 250 list and Inc Fastest Growing Companies list. Rajia raised $3 million to develop invisaWear's technology, scaled the company to over $20 million in sales, and secured powerhouse partnerships with ADT and TELUS Communications, two of the most respected names in the security industry. With over 3 million social media followers, Rajia isn't just building a company — she's building a global movement to make safety accessible to all. In 2023, she launched Smart Alert Holdings, a company focused on acquiring businesses that share the same mission of creating a safer world. Their first acquisition was Flare Safety, invisaWear's only competitor. Her companies have been featured on Good Morning America, ABC News, CBS, WBZ, TODAY, and more. They've also earned prestigious accolades, including TIME Magazine's Best Inventions, Fast Company's Innovation by Design Award, and the New England Innovation Award. As a minority female CEO, Rajia is passionate about breaking barriers for women and underrepresented groups in tech. Her journey of overcoming obstacles fuels her mission to inspire the next generation of entrepreneurs — proving that no matter your background or the doubts you face, success is possible. Rajia remains deeply committed to mentorship through UMass Lowell's Entrepreneurship Program, helping others turn bold ideas into reality. SOCIAL MEDIA: Connect with HeHe on Instagram  Connect with Rajia and InvisaWear on IG    BIRTH EDUCATION: Join The Birth Lounge for judgment-free, evidence-based childbirth education that shows you exactly how to navigate hospital policies, avoid unnecessary interventions, and have a trauma-free labor experience, all while feeling wildly supported every step of the way Want prep delivered straight to your phone? Download The Birth Lounge App for bite-sized birth and postpartum tools you can use anytime, anywhere. And if you haven't grabbed it yet… Snag my free Pitocin Guide to understand the risks, benefits, and red flags your provider may not be telling you about, so you can make informed, powerful decisions in labor.   LINKS MENTIONED: Get 10% off InvisaWear with code HEHE If you're over peeing on sticks, overthinking charts, or trying to take your temp at the same time every morning, Tempdrop does the work for you while you sleep. Grab a discount with code AFHEHE at tempdrop.com/discount/AFHEHE.  

Jamie Siminoff is the CEO and founder of Ring, the camera company that transformed home security. While his viral Shark Tank episode didn't yield a deal from the sharks, it launched the video doorbell company. In 2018, Ring sold to Amazon for $1 billion. Jame published a book titled Ding Dong: How Ring Went from Shark Tank Reject to Everyone's Front Door.  In this episode we discuss:  -the greatest lessons from his failures -the 1 question he'd ask James Dyson in an elevator -why often the most important decisions are the ones we say "no" to -how the best thing that never happened was not getting acquired by ADT -what he learned about the relationship between money and happiness -the best career advice he ever received -the nicest thing anyone has ever done for him and more -- go to www.omaid.me to sign up for the Career Compass newsletter where I share the best career advice from high achievers 

Pat Lencioni, founder of The Table Group and bestselling author behind The Five Dysfunctions of a Team and The 6 Types of Working Genius, joined us on The Modern People Leader. We talked about his origin story in organizational health, how Working Genius helps leaders prevent burnout by designing teams around strengths, and how HR leaders can build trust and stay grounded as AI reshapes work.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode273Sponsor Links:

Brandon Sammut (Chief People and AI Transformation Officer at Zapier), Jenny Molyneaux (VP of People, Vercel), and Valerie Gobeil (Head of Talent Management, Workleap) joined us for a live session on how HR teams are actually using AI today. We talked about how to get organizations AI-ready, avoid “AI debt,” make smarter build vs buy decisions, and we walked through live demos of AI-powered performance reviews, hiring workflows, interview coaching, engagement insights, and more.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode272Sponsor Links:

One, two, three-some! It's the more the merrier this holiday season! This week's episode we're diving into sex, threesomes, and swingers. Alex and Jon have definitely considered an open marriage…if one of them was dead. No judgements for couples that do! Jon just doesn't like to share and Alex can't have more people falling in love with her. Submit your questions here!⁠0:00 - Intro38:03 - Sex Postpartum39:25 - Are Foot Fetishes Weird?40:37 - I Want To See My BF's Butthole43:30 - How Do You Teach Sex?46:43 - My Husband's Into Voyeurism 51:22 - Mismatched Sex Drive55:35 - Swingers01:02:15 - Reading Your Secets01:10: 22 - Recs of the WeekAura Frames: Get $35 off with code: STRAIGHT at https://AuraFrames.comNeiman Marcus: If you're looking for gifts that are guaranteed to surprise and delight, head to Neiman Marcus.ADT: Visit https://ADT.com or call 1-800-ADT-ASAPVital Vitamins: Vital Vitamins is offering listeners 20% of all orders with code STRAIGHT at https://myvitalvitamins.com.Branch Basics: Head to BranchBasics.com to shop their Premium Starter Kit and save 15% off with code STRAIGHT at https://BranchBasics.com.Google: Shop the 100 products that made our year by visiting https://g.co/shop/holiday100Visit our website ⁠www.giveittomestraightpodcast.com⁠Visit our other website ⁠www.alexjon.com⁠Find us on Instagram!⁠Podcast⁠⁠Alex⁠⁠JonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

DJ Casto joined us on The Modern People Leader to share how Synchrony is co-designing the future of work with employees.We talked about active listening at scale, building trust by being great not perfect, rethinking leadership for a flexible workforce, and why treating the employee experience like a product creates real business impact.---- Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode271Sponsor Links:

Taylor and Melanie joined The Modern People Leader to unpack how HR teams can get out from under compliance chaos and admin overload to focus on business impact.---- Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode270Sponsor Links:

"Can we get a family photo? Just without you?”. The in-laws are ON ONE this episode. Thanksgiving is this week and Alex and Jon are here to help you stay thankful during the holiday season. From requesting photos without you to believing the earth is flat, family members are really testing the limits to their relationships with our listeners. It's the holidays so even though we are thankful to be around our loved ones, we are sometimes thankful to leave. Submit your questions here!⁠0:00 - Intro43:49 - Are You Having Children?47:22 - The Earth is Flat, Kids!52:41 - A Sibling Quarrel 54:23 - My Parents Need To Back Off56:47 - Family Photo Debacle 59:21 - Sisterhood of the Traveling Parents01:06:58 - You Ruined My Halloween! 01:12:16 - Recs of the WeekADT: Visit https://ADT.com or call 1-800-ADT-ASAPAG1: Head to https://DRINKAG1.com/STRAIGHT to get a FREE WelcomeKit with an AG1 Flavor Sampler and a bottle of Vitamin D3 plus K2, when you first subscribe!AURA FRAMES: Exclusive $45-off Carver Mat at https://on.auraframes.com/STRAIGHT. Promo Code: STRAIGHTCLEAN SAFE PRODUCTS: Go to https://cleansafeproducts.com/STRAIGHT now to get $15 off the Green Mitt Kit.FACE FOUNDRIE: Visit https://facefoundrie.com and use code GITMS at checkout for 20% off your first service.BOBBIE: If you want to feel good about what's in your baby's bottle, get 10% off with code straight at https://hibobbie.com.NEIMAN MARCUS: If you're looking for gifts that are guaranteed to surprise and delight, head to Neiman Marcus.Visit our website ⁠www.giveittomestraightpodcast.com⁠Visit our other website ⁠www.alexjon.com⁠Find us on Instagram!⁠Podcast⁠⁠Alex⁠⁠JonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode, we had the pleasure of speaking with Daniel Spratt, MD, chair and professor in the Department of Radiation Oncology at Case Western Reserve University School of Medicine and a member of the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr Spratt discussed key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer, including how advances in molecular imaging, evolving systemic therapy options, and the integration of next-generation androgen deprivation therapy (ADT) are reshaping treatment recommendations across localized, recurrent, and advanced disease settings.

Get the cheat sheet: Jamie's 5 steps to build a $1B product from a $200 idea: https://clickhubspot.com/ajn Episode 768: Sam Parr ( ⁠https://x.com/theSamParr⁠ ) and Shaan Puri ( ⁠https://x.com/ShaanVP⁠ ) talk to Ring founder Jamie Siminoff ( https://x.com/JamieSiminoff ) about the wild story of building and selling Ring–plus business ideas he thinks someone should go after.  — Show Notes: (0:00) Intro (2:47) Selling Ring for $1.15B (6:48) Getting sued by ADT (17:18) Working with Jeff Bezos (19:29) $400M to $4B (24:02) Getting the wire (26:44) Money v freedom (28:29) Rule 1: Start with the problem (30:02) Rule 2: Little solution, massive market (33:31) Idea: Modern bug control ($5-10B idea) (40:35) Rule 3: The snowball approach (43:54) Ding Dong and other must reads (46:32) The Tom Brady philosophy on hiring (51:33) The too hard pile (54:25) Stickwithitness (56:14) Last mile marketing (58:08) Rebuilding a town — Links: • Ding Dong - https://tinyurl.com/3zrsjete  • Ring - https://ring.com/  — Check Out Shaan's Stuff: • Shaan's weekly email - https://www.shaanpuri.com  • Visit https://www.somewhere.com/mfm to hire worldwide talent like Shaan and get $500 off for being an MFM listener. Hire developers, assistants, marketing pros, sales teams and more for 80% less than US equivalents. • Mercury - Need a bank for your company? Go check out Mercury (mercury.com). Shaan uses it for all of his companies! Mercury is a financial technology company, not an FDIC-insured bank. Banking services provided by Choice Financial Group, Column, N.A., and Evolve Bank & Trust, Members FDIC — Check Out Sam's Stuff: • Hampton - https://www.joinhampton.com/ • Ideation Bootcamp - https://www.ideationbootcamp.co/ • Copy That - https://copythat.com • Hampton Wealth Survey - https://joinhampton.com/wealth • Sam's List - http://samslist.co/ My First Million is a HubSpot Original Podcast // Brought to you by HubSpot Media // Production by Arie Desormeaux // Editing by Ezra Bakker Trupiano //

Jessica Swank, Chief People Officer at Box, joined us on The Modern People Leader. We talked about building an "org brain", preparing managers to lead teams of humans plus agents, avoiding agent sprawl and tech debt, and why every people leader needs to start experimenting with AI personally to stay ahead.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode269Sponsor Links:

Winter is tough for home inspectors, but it doesn't have to be. In this episode, Mike Crow shares a simple, proven strategy to help you stay profitable during the slow months by adding a referral stream through Secure24.He's joined by Trandon, who supports over 150 inspection companies nationwide and helps them earn a few hundred to several thousand dollars a month by connecting clients with ADT security systems. Mike also shares how this strategy is not just about extra income, but how it can actually help you book more inspections.If you want to hit March 1st with momentum, now is the time to act.Get your tickets to Mission 26 and have your best year ever!Mission 26 Unlock the Power of Mike's #1 Referral-Generating Marketing SystemGet full details here... BBM+ Who is Mike Crow?Mike Crow is a Marketing and Business Expert who has built and managed multiple 7-figure businesses, including two 7-figure inspection firms.For the past 15 years, he's coached thousands of other inspection business owners and has personally helped 100+ companies grow to $1,000,000+ in annual revenue. He has also helped multiple single-inspector operations earn 6-figure annual revenues (some surpassing $300,000).Mike can teach any entrepreneur how to systematize and market their business to achieve their personal and professional goals.

Winter is tough for home inspectors, but it doesn't have to be. In this episode, Mike Crow shares a simple, proven strategy to help you stay profitable during the slow months by adding a referral stream through Secure24.He's joined by Trandon, who supports over 150 inspection companies nationwide and helps them earn a few hundred to several thousand dollars a month by connecting clients with ADT security systems. Mike also shares how this strategy is not just about extra income, but how it can actually help you book more inspections.If you want to hit March 1st with momentum, now is the time to act.Get your tickets to Mission 26 and have your best year ever!Mission 26 Unlock the Power of Mike's #1 Referral-Generating Marketing SystemGet full details here... BBM+ Who is Mike Crow?Mike Crow is a Marketing and Business Expert who has built and managed multiple 7-figure businesses, including two 7-figure inspection firms.For the past 15 years, he's coached thousands of other inspection business owners and has personally helped 100+ companies grow to $1,000,000+ in annual revenue. He has also helped multiple single-inspector operations earn 6-figure annual revenues (some surpassing $300,000).Mike can teach any entrepreneur how to systematize and market their business to achieve their personal and professional goals.

We dug into Foursquare's North Stars of vibrancy and velocity, applying design thinking to the people function, and their team-based performance model.---- Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode268Sponsor Links:

How do you confront your MIL? How do you back out of a wedding? How do you sleep with a newborn? These are questions that Jon and Alex try to answer on this week's episode. With little to no sleep, our new parents tackle wedding woes, passive-aggressive mother-in-laws, and a cake story that will might make you never trust a bakery again. But on a brighter note, Koby is in physical therapy! So the gang is doing alright…they could just use more sleep. Submit your questions here!⁠0:00 - Intro34:36 - Do I Get Them A Gift?39:28 - We Caught Her Stealing!42:47 - GBF Wedding44:25 - My Friend Confessed His Love For Me47:47 - I Need To Back Out of a Wedding50:31 - How Do I Uninvite a Bridesmaid?55:09 - My Best Friend's Third Wedding01:02:18 - My MIL Wore White To My Wedding01:08:11 - Reading Your Secrets01:09:17 - Recs of the WeekADT: Visit https://ADT.com or call 1-800-ADT-ASAPPerelel Health: New customers can enjoy 20% off their first order with code: STRAIGHT. Visit https://perelelhealth.comWayfair: Head to https://wayfair.com now to shop Wayfair's Black Friday deals for up to 70% off.Neiman Marcus: If you're looking for gifts that are guaranteed to surprise and delight, head to Neiman Marcus.Hexclad: Take 10% off at hexclad.com/STRAIGHT and cook like a pro all holiday long. Skims: If you're looking for the perfect gifts for everyone on your list - the SKIMS Holiday Shop is now open at https://SKIMS.com.Branch Basics: For a limited time only, our listeners get 15% off and Free Shipping on their premium starter pack when you use code STRAIGHT at https://BranchBasics.com/STRAIGHT. Visit our website ⁠www.giveittomestraightpodcast.com⁠Visit our other website ⁠www.alexjon.com⁠⁠Podcast⁠⁠Alex⁠⁠JonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shannon Hobbs, Chief People Officer at BNY, joined us to unpack how the bank is scaling its early-career pipeline, flattening org design, and running a culture-first transformation.We discussed BNY's in-house AI hub “Eliza” (99% employee certification, 15k+ agents, 100 digital employees), plus practical advice for CHROs on building AI capability safely and at scale.---- How BNY is betting big on early talent (PDF): https://modernpeopleleader.kit.com/episode267Sponsor Links:

Luke O'Mahoney, Founder & Creator of Sapienˣ, joined The Modern People Leader.We talked about the three emerging models of product-led HR, Agile theater, and how an enterprise company phased its shift to product-led HR.---- Sponsor Links:

In today's episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.

Urinary incontinence and sexual dysfunction are common side effects of prostate cancer treatment, but both are manageable. Dr. Lindsay Hampson explains the types of incontinence—stress, urge, mixed, and overflow—and how identifying the cause guides treatment. Management strategies include pelvic floor physical therapy, medications, and surgical options like slings or artificial urinary sphincters. For sexual dysfunction, approaches range from oral medications and vacuum devices to injections and implants. Dr. Michael Rabow also highlights the side effects of androgen deprivation therapy, including fatigue, depression, hot flashes, and cardiovascular risk. He outlines evidence-based strategies—like exercise, cognitive behavioral therapy, and medications—to help preserve well-being and quality of life during treatment. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40869]

Dr. Geo speaks with cancer immunologist Matthew Halpert, PhD about Immunocine, a dendritic-cell platform that “double-loads” patient-specific tumor signals to trigger a strong, physiologic immune response. Discussion includes mechanism, prostate cancer cases, how it can complement ADT and focal radiation, eligibility, workflow, and access.Chapters00:00 How the Immune System Fights Prostate Cancer02:00 Why dendritic cells matter; generals vs NK/T “soldiers”07:00 The “double-loading” breakthrough and fail-safe concept14:00 Trials in difficult cancers; safety and early signals18:00 Prostate cases: CRPC responses; lesions regressing22:00 Combining with ADT and focal radiation; timing27:00 Critical need for viable tissue; preservation tips34:00 Patient journey: review → tissue + apheresis → 3 doses/6 weeks41:00 Peri-lymphatic delivery; what patients feel; follow-up/boosts49:00 Cost, access, insurance help; foundations; closing takeawaysKey TakeawaysDendritic cells orchestrate immunity; NK/T cells execute.Precision double-loading overcomes a built-in fail-safe to amplify activation.Tissue access and preservation are essential for a broad, personalized target set.Pragmatic combination care: ADT and selective radiation can create a therapeutic window and enhance antigen presentation.________________________

Darren Murph, a leading voice on distributed work and former leader at GitLab, Zillow, and Andela returned to the show.We dug into the remote first maturity scale, the four-pillar operating model (knowledge, project, self, performance), and how to build an “org brain.”---- Sponsor Links:

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care. Episode Highlights: ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs. Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS. Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab. IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes. Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers

Brandon Weber, Co-founder & CEO of Nava Benefits, joined us on The Modern People Leader.We talked about why benefits have become the second-largest company expense — and how HR can “moneyball” their healthcare spend, cut down on benefits-related admin work, and deliver better employee outcomes through the emerging “alt marketplace.”---- Nava Links:

AI has existed for decades, but modern deep learning is finally delivering precision decisions in clinic. Dr. Spratt details how ArteraAI's predictive biomarker—validated on long-term randomized data—can spare roughly two-thirds of eligible men from ADT without compromising outcomes. We unpack ADT's quality-of-life trade-offs, practical training and nutrition strategies to preserve muscle, and where AI is headed next (post-surgery models, higher-risk disease). You'll also hear a clear framework for shared decision-making so men are treated as people, not just numbers.Key Points✅ AI meets prostate cancer. ArteraAI, developed by Dr. Daniel Spratt's team, is now part of the NCCN guidelines—helping doctors know which patients truly benefit from hormone therapy.✅ Two-thirds can skip ADT. Long-term data from the RTOG 9408 trial show most men can avoid the side effects of hormone therapy without affecting outcomes.✅ Quality of life first. Treatments should improve survival or well-being—if they don't, they shouldn't be used.✅ Lifestyle still matters. Exercise, protein, and resistance training help men on ADT preserve muscle and energy.✅ The future is personalized. New AI models will soon guide therapy for higher-risk patients and integrate full-body health data for truly tailored care.⏱️ Time-Stamped Highlights00:00 – Why AI in prostate cancer now? From buzzword to bedside with ArteraAI.01:30 – Deep learning vs. “human-defined” inputs; beyond Gleason to hundreds of slide features.03:10 – Landmark validation: RTOG 9408 and how the model predicts who benefits from ADT.05:00 – ADT trade-offs: longevity vs. libido, energy, bone/muscle; treat only if it improves life or survival.07:15 – “Exercise is medicine”: the 10-minute rule, protein targets, and resistance training on ADT.09:00 – Current indication: primarily intermediate-risk (Gleason 7) men receiving radiation.10:45 – What's next: models for higher-risk and post-prostatectomy patients; shorter-course ADT questions.13:00 – “Black box” & explainability: why robust external validation matters for trust.15:10 – Access & coverage: ordering via online portal; CMS coverage; what patients can ask their doctors.17:20 – Shared decision-making: reduce PSA anxiety; treat the person, not the number.___________________________________

Andrew Golden, Chief People Officer at RetailNext, joined us on The Modern People Leader.We talked about how he's driving transformation, why HR and IT must partner more closely, the power of building lightweight AI solutions in-house, and why he's optimistic about the future of people teams.---- Sponsor Links:

Gena Smith, CHRO at LVMH North America, joined us on The Modern People Leader. We talked about how she sparked an AI transformation across 75 LVMH brands, why HR should lead AI change management, and how to reframe AI adoption as a cultural and creative advantage.---- Sponsor Links:

What happens when you put a mic in front of HR leaders and ask them for their unfiltered takes on AI?In this episode, Daniel and Stephen recap their trip to HR Tech — where they recorded 12 quick-hit “AI Confessions” from folks they met on the conference room floor. From agentic workflows and custom GPT chaos to the real blockers slowing down AI adoption, this one's packed with candid insights from the front lines.You'll hear what HR leaders from companies like Lumen, Articulate, and Airbnb.---- Sponsor Links:

Angela Crossman, Hernan Chiosso, and Jean-Luc Charles joined us to debrief the “Yellow Pod” conversation from MPL Live NYC and what the group is actually doing with AI at work. We covered opportunities vs blockers, “AI as coach” guardrails, why HR should own enablement, actionable next steps, and predictions for the AI-powered workplace.---- Sponsor Links:

"We just want our daughter's remains returned so we can have some closure to our grief."On 15 August 2015, employees at the Mission Park Funeral Chapels North in San Antonio, TX closed up for the evening. They'd just held a service for a young woman named Julie Mott who had perished after a lifelong battle with cystic fibrosis. By 4:30 PM that Saturday, the doors were locked and the ADT alarm system was set.When staff returned to the facility the following morning, they were surprised to see that Julie's casket had been moved from an empty hallway and now rested in a strange position near an exit door. And inside the casket, there was nothing. Her remains were missing...Research by Ira RaiWriting by Amelia WhiteHosting & production by Micheal WhelanLearn more about this podcast at http://unresolved.meIf you would like to support this podcast, consider heading to https://www.patreon.com/unresolvedpod to become a Patron or ProducerBecome a supporter of this podcast: https://www.spreaker.com/podcast/unresolved--3266604/support.

Can high-precision radiation change how we treat metastatic prostate cancer? In this episode, I'm joined by Ronald C. Chen, MD, MPH—radiation oncologist, national guideline author (AUA/ASCO), and clinical-trial leader with 170+ publications—to unpack stereotactic body radiation therapy (SBRT) for disease that has spread to lymph nodes, bones, and beyond. We get practical about who benefits, where SBRT shines, and how to balance treatment intensity with quality of life.SBRT offers highly focused, short-course radiation that can control limited (“oligo-”) metastatic prostate cancer and delay systemic therapy for many men. Dr. Chen explains when to treat individual nodes/bone lesions versus comprehensive nodal fields, how anatomy determines dose/fraction choices (often 3–5 treatments), and why modern SBRT sometimes reduces the need for concurrent hormone therapy. We cover salvage options after prior radiation (brachytherapy seeds, HIFU, cryo, repeat SBRT, or salvage prostatectomy), the role and limits of PSMA PET, fracture risk and bone health (DEXA), and the evolving data—including the large NRG-GU013 trial—for higher-risk disease. Throughout, we emphasize shared decision-making, realistic expectations, and considering clinical trials when data are evolving.00:00 – Can SBRT change metastatic prostate cancer care? Meet Dr. Ron Chen.01:00 – Disclaimer: Views are Dr. Geo's and guests'—independent of NYU Langone.07:00 – Recurrence scenarios: prostate-only, nodal, or bone/other; why catching early matters.12:00 – Five salvage options after prostate radiation: seeds (brachytherapy), HIFU, cryo, SBRT (focal or whole-gland), or salvage prostatectomy.19:00 – Nodal relapse: treat all pelvic nodes + ADT ± abiraterone vs. SBRT to a few nodes only—how patient priorities drive the plan.26:30 – Oligometastasis: SBRT alone can control disease for many men ~2+ years on average, delaying hormones.30:00 – Fractions: why 3–5 treatments is typical and how adjacent bowel/organ anatomy sets the pace.31:00 – SBRT in 2 fractions for select primary cases looks promising; high-risk SBRT under study (NRG-GU013).37:00 – Bone mets: SBRT preferred; understanding fracture risk (tumor size, dose, shrinkage).40:00 – DEXA before ADT; spine SBRT can spare the spinal cord with modern planning.48:00 – Clavicle/hilar nodes: SBRT near lung/heart/esophagus—safe with careful dose constraints.56:00 – Why clinical trials matter for “how long on hormones?” and other open questions.57:00 – Soft-tissue mets (liver/brain): SBRT can help, often alongside systemic therapy.59:00 – Parting advice: early detection, close follow-up, and hopeful trajectory of care.___________________________________

Joy Rothschild, Chief Human Resources Officer at Omni Hotels & Resorts, joined us on The Modern People Leader. ---- Sponsor Links:

This week on The Vergecast, the co-founder and former CEO of iRobot, Colin Angle, joins The Verge's smart home reviewer, Jennifer Pattison Tuohy, to discuss what the ideal home robot is. Are we close to creating a Rosie the Robot — an all-in-one humanoid robot that can take care of our homes, or should we take an entirely different approach to home robotics? They dive into the advances in technology powering this shift and ponder what purpose robotics in the home should really serve. Then, Jen takes a journey back into smart home history to help us understand its future. Grant Erickson, Principal of Nuovations, a former Apple, Nest, and Google engineer who was part of the team that developed Thread, joins the show. He shares the story of how and why, back in 2011, the Nest team, led by Tony Faddell and Matt Rogers, decided to create a smart home protocol. It involves a thermostat, fragmented ecosystems, and one of the best smart home products ever made. They discuss how Thread became the foundation of the Matter smart home standard — an unprecedented industry collaboration with a herculean task — to make the smart home simpler. To close out the show, Grant sticks around to help answer a Vergecast hotline question (call 866-VERGE11 or email vergecast@theverge.com) about how Matter manages your data. Further reading: Maybe I don't want a Rosey the Robot after all Amazon left Roomba with a huge mess to clean up Figure will start ‘alpha testing' its humanoid robot in the home in 2025 Amazon Astro review: too much Alexa, not enough arms Samsung is finally releasing Ballie This Pixar-style dancing lamp hints at Apple's future home robot iRobot's founder is working on a new kind of home robot iRobot OS is the newest ‘brain' for your Roomba Amazon bought iRobot to see inside your home I tested a robot vacuum with an arm, and my dog may never forgive me Inside the Nest: iPod creator Tony Fadell wants to reinvent the thermostat Nest CEO Tony Fadell on Google acquisition Fire drill: Can Tony Fadell and Nest build a better smoke detector? How big companies kill ideas — and how to fight back, with Tony Fadell Situation: there are too many competing smart home standards Matter's plan to save the smart home Nest's home security system costs $499 and comes with magnetic door sensors Google says Matter is still set to fix the biggest smart home frustrations Thread is Matter's secret sauce for a better smart home Nanoleaf launches a smart switch after eight years of trying Thread count: Ikea is stitching together a smarter home Why Thread is Matter's biggest problem right now The four changes in Thread 1.4 that could fix the protocol It could be 2026 before all your Thread border routers work together Matter will be better in 2025 — say the people who make it The Nest Learning Thermostat gets its biggest upgrade in over a decade killedbygoogle.com Google's ADT partnership finally has a new home security product to show for it Google discontinues Nest Protect smoke alarm and Nest x Yale door lock Google discontinues its Google Nest Secure alarm system Appliance makers are teaming up to reduce your electricity usage — and save you cash Learn more about your ad choices. Visit podcastchoices.com/adchoices